PHILADELPHIA - SmithKline Beecham announced it has ended merger discussions with British rival Glaxo Wellcome.
PHILADELPHIA - SmithKline Beecham announced it has ended merger discussions with British rival Glaxo Wellcome.
The surprising decision was made by SmithKline Beecham's board of directors, who previously seemed to be in favor of a merger that would have created the largest pharmaceutical company in the world.
According to a statement released to the press by SmithKline Beecham on Feb. 23, discussions derailed because Glaxo Wellcome would not proceed according to original agreements made about management issues in January.
"In discussions since then, and despite considerable effort on the part of SmithKline Beecham, including initiating a dialogue between SmithKline Beecham's non-executive chairman and Glaxo's non-executive deputy chairman, Glaxo has been unwilling to proceed in accordance with the agreed arrangements," SmithKline Beecham announced.
SmithKline Beecham went on to say that "differences in the approach to the possible merger, management philosophy and corporate culture" and "Glaxo's recent conduct of these discussions" had strained relations between the two companies and prevented the SmithKline Beecham's board from recommending further action.
Glaxo Wellcome, on the other hand, simply announced that merger discussions had ended.
The share value of both companies' stock on the New York Stock Exchange dropped after the announcement. Glaxo Wellcome's share price fell nearly seven points to $551â2 per share, and SmithKline Beecham's dipped six points to $60 per share.
Standard & Poor's, the London-based company that evaluates long-term corporate credit and senior unsecured ratings of publicly traded companies, said the outlook is stable for Glaxo Wellcome and positive for SmithKline Beecham. It also opined that there is no strategic necessity for either company to proceed with a merger in the near future.
Although Glaxo Wellcome could pursue SmithKline Beecham in an unsolicited bid, it is unlikely to do so. Standard & Poor's, for one, indicated that in terms of corporate credit ratings, "debt-financed major strategic moves would likely be viewed negatively." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.